What was recalled
This page synthesizes the acrylamide formation framework in extruded pet food. Acrylamide forms through a specific Maillard-reaction-adjacent pathway: the amino acid asparagine (which has an amide-bearing side chain) reacts with a reducing sugar (glucose or fructose) at high temperature to produce a Schiff base, which undergoes decarboxylation and dehydration to yield acrylamide directly. The temperature threshold is approximately 120°C; below this temperature, acrylamide formation is minimal. Above the threshold, formation rate increases approximately exponentially with temperature.
The kibble extrusion temperature profile typically reaches 110-150°C in the extrusion cook step and 60-110°C in post-extrusion drying. The extrusion-cook portion of the temperature profile is in the acrylamide formation window; the magnitude of formation depends on extrusion-cook temperature, residence time, asparagine content of the starch source, and moisture profile during the cook (lower moisture favors acrylamide formation because the reaction requires the dehydration step). Published pet food acrylamide measurement studies (Becalski 2017, Pedreschi 2014, others) document levels typically in the 100-1,500 ppb range across commercial samples; the highest levels appear in formulations with high potato or potato-protein content (potato is high-asparagine) extruded at temperatures above 135°C.
The regulatory landscape distinguishes between human food and pet food. EU Commission Regulation 2017/2158 established benchmark levels for acrylamide in human foods (potato products, breads, cereals, coffee, infant food) with mandatory monitoring and corrective-action requirements when benchmarks are exceeded. US FDA established guidance levels (non-binding) for human foods (FDA Acrylamide in Foods Guidance 2008, updated 2016) but did not establish mandatory limits. Both EU and US regulatory frameworks for acrylamide explicitly cover human food and do not extend to pet food. Pet food manufacturers may voluntarily implement acrylamide-reduction practices (lower extrusion temperatures, asparagine-reduction supplier specifications, asparaginase enzymatic pre-treatment) but the practices are not regulatorily mandated.
Why it was recalled
The structural concerns have three layers. Layer one — IARC Group 2A classification has chronic-exposure implications: the "probably carcinogenic to humans" classification reflects consistent evidence of acrylamide carcinogenicity in animal models (rats and mice) at chronic dietary exposure levels above approximately 0.5 mg/kg body weight/day, plus limited evidence of association with specific cancer types in human epidemiological studies. The mechanism involves glycidamide (the genotoxic metabolite of acrylamide) and DNA adduct formation. The classification is conservative ("probably" rather than "definitively" carcinogenic) but is the highest carcinogenicity classification short of Group 1.
Layer two — pet exposure characterization is incomplete: pet food acrylamide intake calculations require pet food acrylamide content data (limited published studies) and pet feeding-rate data (typically 1-4% body weight per day depending on pet size, life stage, and activity). For a 30 kg adult dog consuming 400 g/day of 500 ppb acrylamide kibble, daily acrylamide intake is approximately 0.2 mg, or 0.007 mg/kg/day. This is well below the rodent-cancer threshold of 0.5 mg/kg/day but is non-trivial as chronic-exposure intake. Cat exposure can be higher per body weight due to higher per-kg feeding rate. The aggregate chronic-cancer risk for pets consuming extruded kibble has not been characterized in peer-reviewed literature comparable to the human-food research.
Layer three — reduction practices are technologically feasible but not standard: acrylamide reduction in extruded pet food is feasible through several pathways: (i) reducing extrusion-cook temperatures to <120°C where formation is minimal (compatible with low-temperature extrusion but reduces production throughput); (ii) asparaginase enzymatic pre-treatment of starch ingredients (used routinely in some human food categories; rare in pet food); (iii) reducing reducing-sugar content (compatible with formulation revision); (iv) post-extrusion vacuum-cooling to limit acrylamide formation in the drying step. None of these practices are routinely disclosed at the consumer-facing tier. Related framework: extrusion temperature framework.
Health risks for your pet
Direct health risks from acrylamide in extruded pet food at typical exposure levels are uncharacterized in companion-animal-specific peer-reviewed literature. Indirect health considerations drawn from human-food and rodent-model research: (i) chronic cancer risk — IARC Group 2A classification implies non-trivial chronic carcinogenicity risk; the rodent-model threshold (0.5 mg/kg/day) is well above typical pet exposure (0.005-0.015 mg/kg/day) but the dose-response curve at low chronic exposure is uncertain; (ii) neurotoxicity — acrylamide is a documented neurotoxin at high acute exposure (industrial-occupational range) but the relevance to chronic low-dose dietary exposure is unclear; (iii) reproductive effects — rodent-model studies document reproductive and developmental effects at chronic dietary exposure; the relevance to companion-animal exposure is uncharacterized. The aggregate health-impact profile is uncertain due to lack of companion-animal-specific research.
The aggregate health-impact characterization across the 2010-2024 window is incomplete. The dominant interpretation in the pet nutrition research community is that pet acrylamide exposure from extruded kibble is below the rodent-model carcinogenicity threshold but is non-trivial chronic exposure that may contribute to oxidative-stress and chronic-disease burden over the pet’s lifespan. The precautionary interpretation supports the broader case for less-processed pet food formats. The non-precautionary interpretation notes that pets consuming extruded kibble live full lifespans and the cancer-attribution to acrylamide specifically (versus other chronic-disease drivers) is not separable in the current evidence base.
What to do if you bought affected product
Pet owners interested in acrylamide-reduction strategies can take several practical approaches: (1) consider less-processed pet food formats — raw frozen, freeze-dried, gently-cooked, and air-dried formats are processed at lower temperatures and carry substantially lower acrylamide loads than extruded kibble; the tradeoff is higher cost and shorter shelf life; (2) within extruded kibble, prefer formulations with lower starch and especially lower potato content — potato is high-asparagine and yields higher acrylamide in extrusion; grain-inclusive and lower-starch formulations typically have lower acrylamide loads than potato-heavy grain-free formulations; (3) look for brands disclosing extrusion temperature or acrylamide-reduction practices — a small minority of brands disclose extrusion conditions or asparaginase pre-treatment; the disclosure is a positive trust signal for processing-method transparency; (4) weight acrylamide considerations within broader rubric evaluation — the KibbleIQ rubric per our methodology evaluates overall ingredient quality and processing approach; acrylamide-specific dimensions are captured indirectly through processing-method scoring; (5) monitor research and regulatory developments — the EU human-food framework may eventually extend to pet food; future US FDA action remains possible; trade-press coverage and academic research are the primary monitoring sources; (6) avoid over-reaction — the absolute acrylamide exposure for pets consuming extruded kibble is well below the rodent-model carcinogenicity threshold; the framework supports moderation and processing-mode diversification rather than complete avoidance of extruded kibble.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 evaluates processing-method tier and starch-content tier per our published methodology; less-processed formats (raw, freeze-dried, gently-cooked) typically score higher at the processing-method axis, and lower-starch formulations score higher at the carbohydrate-content axis. These rubric dimensions capture acrylamide-formation risk indirectly. Future rubric extensions under consideration: an explicit "processing transparency" scoring axis that would reward brands disclosing extrusion conditions or acrylamide-reduction practices, distinct from the underlying processing-method tier scoring. The framework is covered across our Maillard reaction framework, extrusion heat amino acid damage, extrusion temperature framework, advanced glycation end-products, and furosine bound lysine pages. For now, our recommendation: prefer less-processed pet food formats or lower-starch extruded formulations when acrylamide-reduction is a priority; the absolute exposure is below rodent-model carcinogenicity threshold but the framework supports processing-mode diversification.